AEterna Zentaris Inc. (NASDAQ:AEZS) Short Interest Update
AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) was the target of a large increase in short interest in the month of July. As of July 31st, there was short interest totalling 1,920,407 shares, an increase of 121.9% from the July 14th total of 865,410 shares. Based on an average daily volume of 12,000,600 shares, the days-to-cover ratio is presently 0.2 days. Currently, 19.4% of the company’s shares are sold short.
A number of equities analysts have recently weighed in on the company. Maxim Group set a $4.00 price target on AEterna Zentaris and gave the stock a “buy” rating in a report on Friday. Zacks Investment Research upgraded AEterna Zentaris from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. Finally, HC Wainwright set a $3.00 price target on AEterna Zentaris and gave the stock a “buy” rating in a report on Wednesday, July 5th.
AEterna Zentaris (NASDAQ:AEZS) opened at 2.04 on Friday. The stock’s market capitalization is $29.24 million. The company’s 50-day moving average price is $1.56 and its 200-day moving average price is $2.08. AEterna Zentaris has a one year low of $0.78 and a one year high of $5.59.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.05. AEterna Zentaris had a negative return on equity of 502.76% and a negative net margin of 1,945.78%. The company had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.22 million. The firm’s revenue for the quarter was up 153.1% compared to the same quarter last year. Equities research analysts predict that AEterna Zentaris will post ($1.36) EPS for the current year.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.